CL2016002934A1 - Anticuerpos humanos frente a la proteína de anclaje del coronavirus causante del síndrome respiratorio de oriente medio - Google Patents

Anticuerpos humanos frente a la proteína de anclaje del coronavirus causante del síndrome respiratorio de oriente medio

Info

Publication number
CL2016002934A1
CL2016002934A1 CL2016002934A CL2016002934A CL2016002934A1 CL 2016002934 A1 CL2016002934 A1 CL 2016002934A1 CL 2016002934 A CL2016002934 A CL 2016002934A CL 2016002934 A CL2016002934 A CL 2016002934A CL 2016002934 A1 CL2016002934 A1 CL 2016002934A1
Authority
CL
Chile
Prior art keywords
coronavirus
human antibodies
antibodies against
respiratory syndrome
anchor protein
Prior art date
Application number
CL2016002934A
Other languages
English (en)
Spanish (es)
Inventor
Christos Kyratsous
Neil Stahl
Sumathi Sivapalasingam
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002934(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2016002934A1 publication Critical patent/CL2016002934A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
CL2016002934A 2014-05-23 2016-11-17 Anticuerpos humanos frente a la proteína de anclaje del coronavirus causante del síndrome respiratorio de oriente medio CL2016002934A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462002233P 2014-05-23 2014-05-23
US201462004971P 2014-05-30 2014-05-30
US201462051717P 2014-09-17 2014-09-17
US201462072716P 2014-10-30 2014-10-30

Publications (1)

Publication Number Publication Date
CL2016002934A1 true CL2016002934A1 (es) 2017-11-03

Family

ID=53276323

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002934A CL2016002934A1 (es) 2014-05-23 2016-11-17 Anticuerpos humanos frente a la proteína de anclaje del coronavirus causante del síndrome respiratorio de oriente medio

Country Status (19)

Country Link
US (3) US9718872B2 (OSRAM)
EP (1) EP3145539A1 (OSRAM)
JP (4) JP6934722B2 (OSRAM)
KR (1) KR102371300B1 (OSRAM)
CN (2) CN106414496B (OSRAM)
AU (1) AU2015264189B2 (OSRAM)
BR (1) BR112016025009B1 (OSRAM)
CA (1) CA2949438A1 (OSRAM)
CL (1) CL2016002934A1 (OSRAM)
EA (1) EA036023B1 (OSRAM)
IL (1) IL248392B2 (OSRAM)
JO (1) JO3701B1 (OSRAM)
MA (1) MA40688A (OSRAM)
MX (1) MX373581B (OSRAM)
MY (1) MY180741A (OSRAM)
PH (1) PH12016502064A1 (OSRAM)
SG (1) SG11201608567YA (OSRAM)
WO (1) WO2015179535A1 (OSRAM)
ZA (1) ZA201607047B (OSRAM)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN106928326B (zh) * 2015-12-31 2019-12-24 中国科学院微生物研究所 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN107298712B (zh) * 2016-04-14 2020-04-07 中国疾病预防控制中心病毒病预防控制所 全人源化抗中东呼吸综合征冠状病毒中和抗体
TW201815821A (zh) * 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
IL264631B2 (en) 2016-08-16 2024-05-01 Regeneron Pharma A method for quantifying individual antibodies from a mixture
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
EP4071469B1 (en) 2016-10-25 2025-04-09 Regeneron Pharmaceuticals, Inc. Methods for chromatography data analysis
KR20180058206A (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
JP2020505037A (ja) * 2017-01-19 2020-02-20 オープン モノクローナル テクノロジー，インコーポレイテッド 複数の重鎖免疫グロブリン遺伝子座を有するトランスジェニックげっ歯類由来のヒト抗体
KR20200010390A (ko) 2017-05-22 2020-01-30 에프. 호프만-라 로슈 아게 치료 화합물 및 조성물, 및 이의 사용 방법
SG11201912548XA (en) 2017-07-06 2020-01-30 Regeneron Pharma Cell culture process for making a glycoprotein
KR101895228B1 (ko) * 2017-08-23 2018-10-30 대한민국 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
US11230592B2 (en) 2017-09-27 2022-01-25 The Wistar Institute Of Anatomy And Biology DNA antibody constructs for use against middle east respiratory syndrome coronavirus
WO2019078600A1 (ko) * 2017-10-19 2019-04-25 (주)에이티젠 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
BR112020010615A2 (pt) 2017-12-22 2020-10-27 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
WO2019151632A1 (ko) * 2018-01-31 2019-08-08 (주)셀트리온 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
SG11202005235WA (en) 2018-01-31 2020-07-29 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities
KR20190093107A (ko) * 2018-01-31 2019-08-08 (주)셀트리온 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202516175A (zh) 2018-03-19 2025-04-16 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11696948B2 (en) 2018-06-12 2023-07-11 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
US11690907B2 (en) 2018-06-12 2023-07-04 Kbio Holdings Limited Vaccines formed by virus and antigen conjugation
CN110616198B (zh) * 2018-06-19 2021-02-19 清华大学 一种基于黑猩猩腺病毒68型和MERS-CoV全长膜蛋白的新型冠状病毒疫苗
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
KR102682192B1 (ko) * 2018-08-17 2024-07-04 한림대학교 산학협력단 메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CA3100038A1 (en) 2018-08-30 2020-03-05 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
RU2709659C1 (ru) * 2018-09-06 2019-12-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты)
KR102007161B1 (ko) * 2018-11-07 2019-08-07 대한민국 메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체
MX2021008590A (es) 2019-01-16 2021-08-11 Regeneron Pharma Metodos para caracterizar enlaces de disulfuro.
US20220275059A1 (en) * 2019-02-20 2022-09-01 Harbour Antibodies Bv Antibodies
US11364276B2 (en) 2019-03-26 2022-06-21 National Guard Health Affairs Antiviral peptides for treatment of the middle east respiratory syndrome
SG11202108451VA (en) * 2019-04-03 2021-09-29 Regeneron Pharma Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
KR102213745B1 (ko) * 2019-04-16 2021-02-09 주식회사 바이오앱 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
MX2021013519A (es) 2019-05-13 2021-12-10 Regeneron Pharma Ensayos de union de ligandos competitivos mejorados.
KR20220070262A (ko) * 2019-09-23 2022-05-30 서울대학교산학협력단 항-mers-cov 항체 및 이의 용도
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
JP7682174B2 (ja) 2019-11-25 2025-05-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 非水性エマルションを使用した持続放出製剤
MY200781A (en) 2020-01-21 2024-01-15 Regeneron Pharma Deglycosylation methods for electrophoresis of glycosylated proteins
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN111592602B (zh) * 2020-02-10 2021-03-02 中国科学院微生物研究所 一种β冠状病毒抗原、其制备方法和应用
AU2021219671A1 (en) 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
SMT202300397T1 (it) 2020-02-26 2024-01-10 Vir Biotechnology Inc Anticorpi contro sars-cov-2
CN113321713B (zh) * 2020-02-28 2022-11-01 深圳市亚辉龙生物科技股份有限公司 SARS-CoV-2的重组RBD蛋白及其制备方法
CN116096742A (zh) * 2020-03-09 2023-05-09 雅伯希勒拉生物公司 抗冠状病毒抗体及使用方法
US20210283243A1 (en) * 2020-03-11 2021-09-16 Ibio, Inc. Lichenase-covid-19 based vaccine
US12268707B2 (en) * 2020-03-12 2025-04-08 Sydney David Cullis-Hill Treatment for coronavirus infection and associated cytokine toxicity
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
WO2021207948A1 (en) * 2020-04-14 2021-10-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-sars-cov-2 antibodies and uses thereof
FI4045533T3 (fi) 2020-03-26 2024-02-02 Univ Vanderbilt Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
WO2021201679A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting coronaviruses
CN115884764A (zh) * 2020-04-01 2023-03-31 硫创治疗公司 用于治疗乙型冠状病毒感染的半胱胺前体化合物
KR102831970B1 (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
WO2021216876A2 (en) * 2020-04-24 2021-10-28 The Board Of Regents Of The University Of Texas System Antibodies to coronavirus spike protein and methods of use thereof
US20230210848A1 (en) * 2020-04-30 2023-07-06 Fujifilm Toyama Chemical Co., Ltd. Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug
GB202007532D0 (en) * 2020-05-20 2020-07-01 Alchemab Therapeutics Ltd Polypeptides
WO2021238910A1 (en) * 2020-05-25 2021-12-02 Guo Bingshi Anti-coronavirus spike protein antibodies and uses thereof
EP4157868A1 (en) 2020-05-26 2023-04-05 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN111606981B (zh) * 2020-05-27 2022-02-08 中国医学科学院基础医学研究所 Sars-cov冠状病毒s1蛋白多肽及其应用
US11999777B2 (en) * 2020-06-03 2024-06-04 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing SARS-CoV-2 infections and COVID-19 with anti-SARS-CoV-2 spike glycoprotein antibodies
US20230227539A1 (en) * 2020-06-16 2023-07-20 Hifibio (Hk) Limited Methods and compositions related to neutralizing antibodies against human coronavirus
WO2021260052A1 (en) * 2020-06-23 2021-12-30 Navigo Proteins Gmbh Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2)
WO2022019711A1 (ko) * 2020-07-24 2022-01-27 (주)셀트리온 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자
WO2022026807A2 (en) * 2020-07-30 2022-02-03 Albert Einstein College Of Medicine Antibodies targeting sars-cov-2 and uses thereof
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
US20230357365A1 (en) * 2020-08-07 2023-11-09 Novelgen Co., Ltd. Antiviral composition against coronavirus
CA3192999A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
WO2022054068A1 (en) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Antibodies for the prevention, treatment and detection of coronavirus infection
WO2022060906A1 (en) * 2020-09-15 2022-03-24 Duke University Coronavirus antibodies and uses thereof
US20230303666A1 (en) * 2020-09-24 2023-09-28 The Broad Institute, Inc. Cell-free antibody engineering platform and neutralizing antibodies for sars-cov-2
CN112379087B (zh) * 2020-10-21 2022-02-11 中国医学科学院医学生物学研究所 一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法
IL303027A (en) 2020-11-25 2023-07-01 Regeneron Pharma Sustained release formulations by creating a non-aqueous membrane emulsion
CA3205135A1 (en) 2020-12-17 2022-06-23 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CN114716541B (zh) * 2021-01-05 2023-07-21 中国科学院分子细胞科学卓越创新中心 抗冠状病毒的全人广谱中和抗体76e1及其应用
WO2022150809A1 (en) * 2021-01-05 2022-07-14 Immunome, Inc. Antibody cocktail against sars-cov-2 spike protein
CA3202197A1 (en) 2021-01-20 2022-07-28 Reginald Smith Methods of improving protein titer in cell culture
EP4281468A4 (en) * 2021-01-22 2025-07-09 Henry M Jackson Found Advancement Military Medicine Inc MONOCLONAL ANTIBODIES AGAINST CORONAVIRUSES AND THEIR USES
WO2022170126A2 (en) * 2021-02-05 2022-08-11 Adagio Therapeutics, Inc. Compounds specific to coronavirus s protein and uses thereof
WO2022182662A1 (en) 2021-02-23 2022-09-01 10X Genomics, Inc. Compositions and methods for mapping antigen-binding molecule affinity to antigen regions of interest
CA3210655A1 (en) * 2021-03-02 2022-09-09 Novarock Biotherapeutics, Ltd. Antibodies against claudin-6 and uses thereof
US20220404369A1 (en) 2021-03-03 2022-12-22 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
WO2022197664A1 (en) * 2021-03-15 2022-09-22 Emory University Sars-cov-2 antibodies and fragments, therapeutic uses, diagnostic uses, and compositions related thereto
WO2022212654A2 (en) * 2021-04-02 2022-10-06 The Scripps Research Institute Cross-reactive monoclonal antibodies against coronaviruses
WO2022241200A1 (en) * 2021-05-14 2022-11-17 Vanderbilt University Cross-reactive coronavirus antibodies
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
MX2024000563A (es) 2021-07-14 2024-04-10 Regeneron Pharma Anticuerpos y fragmentos de union al antigeno anti-glicoproteína de la espícula de sars-cov-2.
WO2023004431A2 (en) * 2021-07-23 2023-01-26 The Trustees Of Columbia University In The City Of New York Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
AU2022348521A1 (en) 2021-09-20 2024-04-04 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
CN116178530A (zh) * 2021-09-26 2023-05-30 上海君实生物医药科技股份有限公司 抗体在治疗SARS-CoV-2感染的用途
MX2024004108A (es) 2021-10-07 2024-04-19 Regeneron Pharma Calibracion y correccion de medidor de ph.
EP4413364A2 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
US20240409619A1 (en) * 2021-10-13 2024-12-12 The Wistar Institute Of Anatomy And Biology Antibodies for use against sars-cov-2
IL312372A (en) 2021-10-26 2024-06-01 Regeneron Pharma Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023178182A1 (en) 2022-03-16 2023-09-21 10X Genomics, Inc. Compositions and methods for detection and treatment of coronavirus infection
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024229136A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
TW202532098A (zh) 2023-09-29 2025-08-16 美商再生元醫藥公司 使用控制成核之冷凍乾燥
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
CN119264262B (zh) * 2024-09-19 2025-09-02 中山大学 一种双特异性抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2522379C (en) * 2003-04-10 2012-10-23 Chiron Corporation The severe acute respiratory syndrome coronavirus
CN1914226B (zh) * 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
WO2014045254A2 (en) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
CN103554244B (zh) * 2013-05-09 2016-09-07 香雪集团(香港)有限公司 具有抑制呼吸道病毒感染的活性的肽及其应用和制备方法
CN103554235B (zh) * 2013-06-17 2015-06-24 清华大学 MERS-CoV病毒膜蛋白中的RBD片段及其编码基因和应用
KR20160145813A (ko) * 2014-04-25 2016-12-20 다나-파버 캔서 인스티튜트 인크. 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법
JO3701B1 (ar) * 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EP3381279B1 (en) * 2014-05-30 2021-04-14 Regeneron Pharmaceuticals, Inc. Humanized dipeptidyl peptidase iv (dpp4) animals

Also Published As

Publication number Publication date
CN106414496A (zh) 2017-02-15
US20190351049A1 (en) 2019-11-21
US20150337029A1 (en) 2015-11-26
CN114057869A (zh) 2022-02-18
US9718872B2 (en) 2017-08-01
EA201691877A1 (ru) 2017-03-31
BR112016025009B1 (pt) 2022-08-02
JP2017524339A (ja) 2017-08-31
IL248392B2 (en) 2023-12-01
NZ725885A (en) 2022-04-29
JP2024123027A (ja) 2024-09-10
EP3145539A1 (en) 2017-03-29
CA2949438A1 (en) 2015-11-26
KR20170005133A (ko) 2017-01-11
US10406222B2 (en) 2019-09-10
JP7500812B2 (ja) 2024-06-17
JP2021129594A (ja) 2021-09-09
MA40688A (fr) 2017-03-28
JP6934722B2 (ja) 2021-09-15
EA036023B1 (ru) 2020-09-15
IL248392A0 (en) 2016-11-30
IL248392B1 (en) 2023-08-01
MX373581B (es) 2020-05-05
BR112016025009A2 (pt) 2017-10-24
ZA201607047B (en) 2017-09-27
KR102371300B1 (ko) 2022-03-07
MX2016015263A (es) 2017-03-23
JP7297814B2 (ja) 2023-06-26
AU2015264189B2 (en) 2021-03-25
SG11201608567YA (en) 2016-11-29
JP2023085425A (ja) 2023-06-20
JO3701B1 (ar) 2021-01-31
CN114057869B (zh) 2025-06-24
AU2015264189A1 (en) 2016-11-17
MY180741A (en) 2020-12-08
WO2015179535A1 (en) 2015-11-26
CN106414496B (zh) 2021-11-30
US20170340728A1 (en) 2017-11-30
PH12016502064A1 (en) 2016-12-19

Similar Documents

Publication Publication Date Title
CL2016002934A1 (es) Anticuerpos humanos frente a la proteína de anclaje del coronavirus causante del síndrome respiratorio de oriente medio
EP3491945A4 (en) FLAVOR INHALER
DK3474804T3 (da) Medicinsk forbinding
EP4397341C0 (en) AROMA INHALER
IL262776A (en) Humanized anti-il-1r3 antibodies
DK3233903T3 (da) Kimære antigenreceptorer og anvendelsesfremgangsmåder
DK3377634T3 (da) Bakteriebaseret proteinafgivelse
GB2526430B (en) Joint mechanism and child high chair thereof
DK3203937T3 (da) Subtalarledimplantat
EP3347042A4 (en) MULTIVALENT PPV CONJUGATES
SG11201802754XA (en) Blood preparation and profiling
DK3474803T3 (da) Medicinsk forbinding
EP3443854C0 (en) AROMA INHALER
DK3132031T3 (da) Carbohydratbindende protein
EP3313974A4 (en) NON-INVASIVE REFRACTOMETER
EP4233950C0 (en) NASAL ADMINISTRATION
DE102014018519A8 (de) Elastischer Gelenkkörper
ES1138710Y (es) Aparato anti-ronquido y apnea.
TH1501005571A (th) แอนติบอดี pac1 ของมนุษย์
FI10620U1 (fi) Liitosrakenne ja tuoli
UA34173S (uk) Пробка медична
UA34172S (uk) Пробка медична
UA34111S (uk) Пробка медична
UA34174S (uk) Пробка медична
UA34110S (uk) Пробка медична